These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 18220499)

  • 21. Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis.
    Kusamori K; Katsumi H; Abe M; Ueda A; Sakai R; Hayashi R; Hirai Y; Quan YS; Kamiyama F; Sakane T; Yamamoto A
    J Bone Miner Res; 2010 Dec; 25(12):2582-91. PubMed ID: 20533374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alendronate: an update of its use in osteoporosis.
    Sharpe M; Noble S; Spencer CM
    Drugs; 2001; 61(7):999-1039. PubMed ID: 11434454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy.
    Greenspan SL; Nelson JB; Trump DL; Wagner JM; Miller ME; Perera S; Resnick NM
    J Clin Oncol; 2008 Sep; 26(27):4426-34. PubMed ID: 18802155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once weekly alendronate.
    Sambrook P
    Drugs Today (Barc); 2003 May; 39(5):339-46. PubMed ID: 12861347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Short Term Alendronate Administration on Bone Mineral Density in Patients with Chronic Kidney Disease.
    Aggarwal HK; Jain D; Chhabra P; Yadav RK
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2018 Jul; 39(1):5-13. PubMed ID: 30110263
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
    Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
    Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Drug therapy of secondary osteoporosis: glucocorticoid-induced osteoporosis].
    Soen S
    Nihon Rinsho; 2009 May; 67(5):985-90. PubMed ID: 19432121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention and treatment of glucocorticoid-induced osteoporosis in 2005.
    Orcel P
    Joint Bone Spine; 2005 Dec; 72(6):461-5. PubMed ID: 16326129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy of teriparatide in treatment of glucocorticoid-induced osteoporosis].
    Soen S
    Clin Calcium; 2012 Mar; 22(3):315-20. PubMed ID: 22370297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial.
    Hoes JN; Jacobs JW; Hulsmans HM; De Nijs RN; Lems WF; Bruyn GA; Geusens PP; Bijlsma JW
    Clin Exp Rheumatol; 2010; 28(3):354-9. PubMed ID: 20406615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy.
    Okada Y; Nawata M; Nakayamada S; Saito K; Tanaka Y
    J Rheumatol; 2008 Nov; 35(11):2249-54. PubMed ID: 19031508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.
    Jansen JP; Gaugris S; Bergman G; Sen SS
    Curr Med Res Opin; 2008 Mar; 24(3):671-84. PubMed ID: 18221588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacological and clinical profile of once weekly alendronate for the treatment of osteoporosis (Fosamac 35 mg/Bonalon 35 mg)].
    Uchida S; Azuma Y; Taniguchi T; Arizono H; Shimizu T; Okaniwa M; Nakamura K; Ohta T
    Nihon Yakurigaku Zasshi; 2007 Oct; 130(4):305-12. PubMed ID: 17938517
    [No Abstract]   [Full Text] [Related]  

  • 35. Prevention of glucocorticoid-induced osteoporosis.
    van Brussel MS; Bultink IE; Lems WF
    Expert Opin Pharmacother; 2009 Apr; 10(6):997-1005. PubMed ID: 19351276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of alendronate after 5 years of treatment.
    Delmas PD
    JAMA; 2007 May; 297(18):1979-80; author reply 1980-1. PubMed ID: 17488957
    [No Abstract]   [Full Text] [Related]  

  • 37. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
    Wells GA; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
    Cochrane Database Syst Rev; 2008 Jan; (1):CD001155. PubMed ID: 18253985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alendronate for the treatment of osteoporosis in men.
    Orwoll E; Ettinger M; Weiss S; Miller P; Kendler D; Graham J; Adami S; Weber K; Lorenc R; Pietschmann P; Vandormael K; Lombardi A
    N Engl J Med; 2000 Aug; 343(9):604-10. PubMed ID: 10979796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug injury in the upper gastrointestinal tract: effects of alendronate.
    Khapra AP; Rose S
    Gastrointest Endosc Clin N Am; 2006 Jan; 16(1):99-110. PubMed ID: 16546026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
    Saag KG; Emkey R; Schnitzer TJ; Brown JP; Hawkins F; Goemaere S; Thamsborg G; Liberman UA; Delmas PD; Malice MP; Czachur M; Daifotis AG
    N Engl J Med; 1998 Jul; 339(5):292-9. PubMed ID: 9682041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.